Gerald Williams, DO
Internal Medicine · Kansas City, MONPI 1982695987
Payments from drug & device makers
Across 187 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$477
- Lilly USA, LLC$404
- Pfizer$311
- Novo Nordisk$290
- Amgen$244
- AbbVie$202
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,94999%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $477 |
| Lilly USA, LLC | 24 | $404 |
| Pfizer | 29 | $311 |
| Novo Nordisk | 17 | $290 |
| Amgen(2 entities) | 16 | $244 |
| AbbVie | 10 | $202 |
| Merck | 12 | $179 |
| Abbott | 9 | $173 |
| GSK | 5 | $70 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Teva Pharmaceuticals USA, Inc. | 5 | $61 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Boston Scientific | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Boehringer Ingelheim | 2 | $44 |
| Radius Health, Inc. | 1 | $32 |
| Johnson & Johnson | 2 | $30 |
| Biogen | 2 | $26 |
| Dexcom, Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 2 | $24 |
| Vertex | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Abiomed | 1 | $17 |
| Celltrion USA Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| BD | 1 | $12 |
| Endogastric Solutions, Inc | 2 | $10 |
How this compares
$2,965 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $105,593 |
| FarxigaDapagliflozin Propanediol | 44 | $51,552 |
| JardianceEmpagliflozin | 38 | $47,226 |
| EliquisApixaban | 41 | $37,159 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,141 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,038 |
| RestasisCyclosporine | 11 | $6,863 |
| Varenicline Tartrate | 33 | $6,172 |
| Gabapentin | 227 | $4,276 |
| Ezetimibe | 202 | $3,834 |
| Celecoxib | 70 | $3,426 |
| Rosuvastatin Calcium | 135 | $2,853 |
| Omeprazole | 120 | $2,678 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,237 |
| Atorvastatin Calcium | 243 | $1,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $290 | $105,59387 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $477 | $60,59058 claims |
| Boehringer IngelheimJardiance | $44 | $47,22638 claims |
| PfizerEliquis | $311 | $37,15941 claims |
| GSKTrelegy Ellipta | $70 | $15,14115 claims |
| AbbVieRestasis | $202 | $6,86311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Kansas City
- Craig DietzKansas City$4M
- Santosh SharmaKansas City$782K
- Kevin SuttmoellerKansas City$198K
- Karla Houston-GrayKansas City$24K
- Timothy SmithSaint Peters$21.4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Jianbo WangChesterfield$643K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.